RegenLab® is recognized as a certified global leader in medical biotechnologies, specializing in cellular therapies. In the United States, RegenLab® USA provides expertly designed Class II medical devices for the preparation of platelet rich plasma from the patient's own blood. Regen® A-PRP® was developed with a focus on product quality, patient safety, and preparation efficiency. Our patient-centered technology has led to over one million treatments provided worldwide using RegenLab® products. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.
Platelets are key factors in hard and soft tissue repair mechanisms. They provide essential growth factors such as FGF, PDGF, TGF-β, EGF, VEGF, and IGF which are involved in stem cell migration, differentiation, and proliferation. By using the patient’s own blood to prepare the platelet concentrate, the RegenKit® technology vastly reduces the risk of an allergic or adverse reaction.
- In Accordance with Quality System Regulations
- Patented Innovations
- +1 Million Patients Treated World Wide
- FDA Cleared and Iso 13485 certified
- Safe & easy to use
- Class II Medical Device
- Non Pyrogenic
- Self contained , closed system
- Consistent Isolation PRP
- Low blood volume required
- Therapeutic platelet recovery
- Over 80 studies indexed on pubmed
- Leading innovations
Since 2003, RegenLab® has been committed to the development of a unique expertise in the design and manufacturing of high-quality medical devices, intended for the preparation of cellular therapies and autologous platelet-rich plasma (PRP) from the patient’s own blood. Bringing these technologies to the United States in 2013, RegenLab® USA offers Regen® A-PRP® and Autologous Thrombin Serum with a focus on product quality, patient safety, and preparation efficiency.
Our patient-centered technology has led to over one million treatments provided worldwide using RegenLab® products. In 2017, a new Good Manufacturing Practice (GMP) facility was completed in Mont-sur-Lausanne, Switzerland (canton of Vaud) allowing RegenLab® to increase access to autologous cellular therapies around the world. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.
Leukocyte Poor PRP
RegenKit® A-PRP® Plus
Autologous Thrombin Serum
Lymphocyte Rich PRP
Leukocyte Poor 20mL PRP
Partners and Affiliations